Sangamo Therapeutics (SGMO) Stock Forecast & Price Target $0.64 -0.05 (-6.54%) Closing price 04:00 PM EasternExtended Trading$0.64 -0.01 (-1.22%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Sangamo Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating HoldBased on 7 Analyst RatingsSell1Hold2Buy4 Based on 7 Wall Street analysts who have issued ratings for Sangamo Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 7 analysts, 1 has given a sell rating, 2 have given a hold rating, and 4 have given a buy rating for SGMO. Consensus Price Target $4.50597.78% Upside According to the 7 analysts' twelve-month price targets for Sangamo Therapeutics, the average price target is $4.50. The highest price target for SGMO is $10.00, while the lowest price target for SGMO is $2.00. The average price target represents a forecasted upside of 597.78% from the current price of $0.64. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for SGMO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sangamo Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SGMO Analyst Ratings Over TimeTypeCurrent Forecast10/16/24 to 10/16/251 Month Ago9/16/24 to 9/16/253 Months Ago7/18/24 to 7/18/251 Year Ago10/17/23 to 10/16/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy4 Buy rating(s)4 Buy rating(s)4 Buy rating(s)1 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)2 Hold rating(s)3 Hold rating(s)Sell1 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$4.50$4.50$4.50$2.67Forecasted Upside597.78% Upside775.15% Upside782.01% Upside168.82% UpsideConsensus RatingHoldModerate BuyModerate BuyHold SGMO Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History SGMO Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Sangamo Therapeutics Stock vs. The CompetitionTypeSangamo TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.43 2.33 2.52Consensus RatingHoldHoldModerate BuyPredicted Upside569.64% Upside996.92% Upside13.10% UpsideNews Sentiment RatingPositive NewsSee Recent SGMO NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/8/2025Weiss Ratings0 of 5 stars Reiterated RatingSell (E+)9/4/2025HC Wainwright2 of 5 starsPatrick R. Trucchio Not RatedReiterated RatingBuy$10.00+1,790.33%5/14/2025Barclays3 of 5 starsGena Wang Not RatedLower TargetOverweight$9.00 ➝ $5.00+984.58%3/18/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLuca IssiSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingSector Perform$2.00 ➝ $2.00+133.10%1/23/2025Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingN. GerminoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$7.00 ➝ $5.00+332.90%12/31/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetBuy$7.00 ➝ $3.00+215.79%12/31/2024Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower TargetEqual Weight$3.00 ➝ $2.00-14.53%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:44 PM ET. SGMO Forecast - Frequently Asked Questions What is Sangamo Therapeutics' forecast for 2025? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Sangamo Therapeutics is $4.50, with a high forecast of $10.00 and a low forecast of $2.00. Should I buy or sell Sangamo Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There is currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares. Does Sangamo Therapeutics's stock price have much upside? According to analysts, Sangamo Therapeutics's stock has a predicted upside of 597.78% based on their 12-month stock forecasts. What analysts cover Sangamo Therapeutics? Sangamo Therapeutics has been rated by research analysts at HC Wainwright, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Sangamo Therapeutics more than its competitors? Analysts like Sangamo Therapeutics more than other "medical" companies. The consensus rating score for Sangamo Therapeutics is 2.43 while the average consensus rating score for "medical" companies is 2.33. Learn more on how SGMO compares to other companies. Stock Forecasts and Research Tools Related Companies GERN Stock Forecast MYGN Stock Forecast VSTM Stock Forecast LXRX Stock Forecast EBS Stock Forecast RIGL Stock Forecast XOMA Stock Forecast VNDA Stock Forecast IRWD Stock Forecast CDXS Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:SGMO) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWall St’s “AI Godfather” breaks his silenceWhats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
